Compare Global X Lithium & Battery Tech ETF (LIT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Natera Inc. Common Stock — how do they compare? Global X Lithium & Battery Tech ETF trades at $65 (market cap $1.45B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 39.3× Global X Lithium & Battery Tech ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 57 Days and Natera Inc. Common Stock for 0 Days on average.
| LIT | NTRA | |
|---|---|---|
Market Cap | $1.45B | $57.03B |
Volume | 191,139 | 1,131,157 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $425.64 |
52-Week Low | $56.39 | $179.42 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $67.65, down 1.05% with bearish technical signals from moving averages and oscillators. The ETF faces headwinds from volatile lithium prices and oversupply concerns, though long-term prospects remain supported by EV adoption trends. Recent news highlights significant short interest reduction and China's ambitious 30% EV fleet target by 2030.
Outlook is cautious near-term due to technical weakness and commodity volatility, but structural EV growth offers recovery potential. Risks include lithium price swings and geopolitical trade tensions, while institutional sentiment shows mixed signals with recent short covering.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
